What are the usage and dosage specifications of tucatinib/tucatinib?

Tucatinib is an oral anti-tumor drug mainly used to treat HER2-positive metastatic breast cancer and colorectal cancer, especially those patients who are resistant to previous treatments. According to current clinical guidelines, the recommended dosage of tucatinib is 300 mg orally twice daily, and patients need to continue taking it until disease progression or unacceptable toxicity occurs. This usage is designed to ensure that the drug maintains effective concentrations in the body to maximize its anti-tumor effect.

When using tucatinib, doctors often recommend combining it with other drugs, such as trastuzumab and capecitabine, to create an effective combination treatment. This combination helps enhance the synergistic effect of treatment and improves patients' overall survival and quality of life. When implementing specific treatments, patients should follow the doctor's instructions and use the medication strictly in accordance with the recommended usage to ensure maximum efficacy and minimize potential adverse reactions.

In addition, patients should undergo regular follow-up examinations during medication to monitor treatment response and side effects. Doctors need to flexibly adjust the medication plan based on the patient's physical condition, laboratory test results, and discomfort during treatment. This personalized treatment strategy helps optimize efficacy and reduce unnecessary risks.

In short, the use of tucatinib must strictly follow relevant clinical guidelines and be performed under the supervision of professional medical personnel. Through scientific and reasonable usage and dosage specifications, tucatinib can provide new hope for patients with HER2-positive metastatic breast cancer and significantly improve their prognosis and quality of life.

Reference materials:https://www.tukysa.com/